Dayvigo (Lemborexant) Storage, Stability & Shelf Life

Dayvigo is the brand name for lemborexant, a prescription-only dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for treating insomnia in adults. It is dispensed as 5 mg and 10 mg tablets in individual foil blister cavities, not in a pill bottle. This article covers how to store those tablets, how long they remain good, and what to do if storage goes wrong. It is not a dosing guide, and it does not replace the manufacturer's printed prescribing information that comes with the medication.

The real question: temperature or the sealed blister?

Most storage guidance for oral tablets focuses on temperature ranges, and Dayvigo's labeled range (controlled room temperature, with defined excursions) is unremarkable for a solid oral drug. The more consequential variable for a typical patient is whether the tablet has stayed inside its original aluminum blister until use. A tablet that sat in a moderately warm room for a few days is very unlikely to have degraded meaningfully. A tablet popped out of its blister into a weekly pill organizer, or left loose on a nightstand, has lost the packaging that was specifically designed to keep moisture and light away from it, and there is no published stability data describing how the tablet performs outside that packaging. That distinction, not the thermostat, is the practical decision point this page is built around.

FDA-labeled storage conditions

Dayvigo's FDA-approved prescribing information directs storage at controlled room temperature, 20°C to 25°C (68°F to 77°F), which is the same standard applied to most oral tablets marketed in the United States. This standard traces to the United States Pharmacopeia's definition of "controlled room temperature," which permits brief excursions between 15°C and 30°C (59°F to 86°F) without treating the product as out of specification.

The label also instructs storing tablets in the original package, which protects against both moisture and light. Manufacturers only add a light-protection instruction to a label when photostability testing (the ICH Q1B methodology, a standard test that exposes a drug substance to defined visible and UV light doses) showed measurable degradation under light exposure. That is a regulatory signal that this is a functional requirement rather than boilerplate caution.

A tablet left in a hot car is a common real-world scenario worth naming directly: cabin temperatures in a parked car can exceed 60°C (140°F) in warm weather, which is well outside the 30°C ceiling for tested excursions. Sustained heat exposure that far outside the labeled range has not been validated by the manufacturer's stability program, so potency cannot be assumed.

Shelf life and expiration dating

The FDA assigns Dayvigo's shelf life based on stability data submitted with the original New Drug Application. Manufacturers commonly generate this data under the ICH Q1A(R2) framework, which requires testing at long-term storage conditions (around 25°C/60% relative humidity), an intermediate condition (around 30°C/65% RH), and an accelerated stress condition (around 40°C/75% RH) to project how the tablet will behave over its dating period. The expiration date printed on the carton and each blister reflects this testing and is the date patients and pharmacists should rely on; it should not be extended informally.

We have not independently verified the exact shelf-life duration or the specific accelerated-testing results Eisai submitted for Dayvigo, and readers should treat any precise month figure as something to confirm against the current FDA-approved label rather than this article. What is not in question: once a tablet is past its printed expiration date, the manufacturer's testing no longer supports its potency or purity, and it should not be used.

Pharmacists dispensing Dayvigo in its original manufacturer packaging (rather than repackaging into vials) apply the printed expiration date directly, since it already reflects container-specific stability data.

Decision framework: is this tablet still safe to take?

Use this as a structured way to think through a storage lapse, not a substitute for calling the dispensing pharmacy when in doubt.

If a situation does not fit cleanly into one of these rows, the safest default is to call the dispensing pharmacy rather than guess.

Packaging and moisture protection

Dayvigo tablets are packaged in unit-dose aluminum blisters, one tablet per sealed cavity. This unit-dose format limits the tablet's exposure to ambient humidity between manufacture and the moment a patient pushes it through the foil. Many oral tablets are sensitive to moisture uptake (a property called hygroscopicity), and manufacturers test for this specifically under high-humidity accelerated conditions as part of the same ICH Q1A(R2) program mentioned above.

Once a tablet is removed from its blister and placed in a pill organizer, pillbox, or loose container, that moisture and light barrier is gone, and there is no published data describing how the tablet performs once removed. A practical, conservative approach recommended in this article: if you use a weekly pill organizer, load only the current week's doses and keep the remaining blisters sealed inside the original carton.

Light sensitivity

The FDA-approved label's instruction to store tablets in the original package, protected from light, reflects photostability testing rather than a generic caution. The sealed aluminum blister provides complete light occlusion. The exposure that matters is prolonged storage outside the blister in clear containers, on a sunlit windowsill, or in a bathroom cabinet under frequent artificial light, not the brief moment of removing and swallowing a tablet.

How lemborexant works, and why that is a separate question from storage

Lemborexant belongs to the dual orexin receptor antagonist (DORA) class. Orexin (also called hypocretin) is a wake-promoting neuropeptide signaling system originating in the hypothalamus; drugs in this class block orexin receptor signaling to reduce wake drive rather than broadly sedating the brain the way older GABA-acting hypnotics do. Randomized controlled trials published in JAMA Network Open and in the journal Sleep evaluated lemborexant against placebo (and, in one trial, against extended-release zolpidem) and reported improvements in objective and patient-reported sleep-onset and sleep-maintenance measures over periods ranging from one month to about a year. We have not independently re-verified the exact effect sizes, sample sizes, or p-values reported in the source material for those trials, and a reader who needs precise figures for clinical decision-making should pull the primary trial publications directly rather than relying on secondhand numbers.

Mechanism of action is included here for context only. It does not change how the tablets should be stored, and receptor binding data are not a substitute for stability testing when judging whether a tablet that was mishandled is still safe to take.

Storage in pharmacy and institutional settings

Hospital pharmacies, long-term care facilities, and mail-order pharmacies face storage questions beyond a single patient's medicine cabinet. Mail-order shipments during hot months can experience temperature excursions in transit; pharmacies that ship temperature-sensitive medications commonly use insulated packaging and, for some drugs, temperature indicators to document that a shipment stayed within an acceptable range. We do not have a verified, drug-specific figure for how often Dayvigo shipments experience excursions, so no such statistic is cited here; a general industry pattern of occasional excursions during summer shipping is well documented in pharmacy logistics literature, but a reader who needs an exact rate should look for current, dated data rather than a number carried over from an unrelated product line.

Automated dispensing cabinets and long-term care storage areas should be checked periodically to confirm they remain within controlled room temperature range, particularly in facilities without central air conditioning during heat waves.

What to do if storage was compromised

A tablet exposed to conditions outside the labeled range is not automatically inert or dangerous, but neither the prescriber nor the pharmacist can guarantee its potency once it has been outside tested conditions. When in doubt, the safest and simplest step is to contact the dispensing pharmacy, describe exactly what happened (how hot, how long, whether the blister was open), and ask whether replacement is warranted. Some insurance plans will authorize an early refill when a storage-related loss is documented, though policy varies by plan and this article cannot state coverage rules generally.

How Dayvigo's storage compares to other insomnia medications

Suvorexant (Belsomra), the other FDA-approved DORA, and sublingual zolpidem (Intermezzo) are also dispensed in blister packaging with similar controlled-room-temperature labeling, reflecting comparable sensitivity to moisture and, for some products, light. Standard zolpidem tablets (Ambien) are commonly dispensed in bottles rather than blisters, which suggests a different moisture-sensitivity profile for that formulation. Ramelteon (Rozerem) is stored at controlled room temperature without a specific light-protection instruction on its label. The takeaway for a patient switching between insomnia medications: do not assume storage habits transfer automatically from one drug to another. Each product's packaging reflects its own stability testing, and the safest approach is to follow the instructions printed with that specific prescription.

What is established, what is plausible, and what is not established

Established: Dayvigo is labeled for controlled room temperature storage with defined excursion limits; the FDA label instructs storing tablets in original packaging, protected from moisture and light; tablets carry a manufacturer-assigned expiration date that should not be exceeded.

Plausible but not independently verified in this article: the exact numeric shelf-life duration, the specific accelerated stability results Eisai submitted, and the precise trial statistics for lemborexant's efficacy. These are the kind of specific figures that should be pulled from the current FDA label or the primary trial publications rather than taken secondhand.

Not established: how long a tablet remains reliably potent once removed from its blister and left exposed to air, light, or humidity for an extended period; whether any specific insurer will cover a replacement fill after a storage mishap; and current generic availability, which changes over time and should be checked against the FDA's Orange Book or a pharmacist at the time of reading rather than assumed from this page.